Medications such as semaglutide (Ozempic) and tirzepatide (Mounjaro), which affect appetite and reward pathways, are now being investigated as pharmacological adjuncts to help people reduce or stop alcohol consumption
Zhao H-J, Jiang X, Hu L-J, Yang L, Deng L-D, Wang Y-P, et al
Those include Ozempic and its sister drug approved for obesity, Wegovy, which use semaglutide, and Mounjaro and Zepbound, for diabetes and obesity, respectively, which use the active ingredient tirzepatide
[DOI] [PubMed] [Google Scholar] 16.Ryan DH, Lingvay I, Deanfield J, et al
Unfortunately, the study was prematurely terminated and underpowered, which precludes a conclusive determination of the disease-modifying effects of exenatide for MCI or early AD in clinical settings [95]